DIDaisuke Irie

Daisuke Irie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daisuke Irie has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term Efficacy and Safety of Carbon-ion Radiotherapy for Thoracic Chordoma: A Case Report

    by Daisuke Irie, Shintaro Shiba, Yuhei Miyasaka, Masahiko Okamoto, Yukihiko Yoshimatsu, Kei Shibuya, Hiroki Kiyohara, Tatsuya Ohno

    We report a case of inoperable thoracic chordoma successfully treated with carbon-ion radiotherapy (C-ion RT). A 65-year-old male patient underwent computed tomography for evaluation of a benign thyroid nodule and was incidentally diagnosed with thoracic chordoma without metastasis. A physical examination revealed increased tendon reflexes in the lower extremities. Magnetic resonance imaging revealed a tumour measuring 52 mm in maximum diameter, located from the seventh cervical to the third thoracic vertebrae, compressing a wide area of the spinal cord. The patient was unsuitable for surgery due to the high risk of severe postoperative neurological dysfunction. The patient received C-ion RT at a total dose of 64.0 Gy (relative biological effectiveness), delivered in 16 fractions. The patient completed C-ion RT as scheduled; however, the patient experienced transient Lhermitte's sign, classified as grade 1 acute neuropathy, during treatment. The patient is alive 96 months after C-ion RT initiation with no evidence of local recurrence or distant metastasis, remains ambulatory, and has developed no grade 2 or higher toxicities other than the grade 1 neuropathy that was present prior to the initiation of C-ion RT. We observed a favourable local response with manageable toxicity in a patient with thoracic chordoma treated with C-ion RT. Although this is a single-case report, our findings suggest that C-ion RT could be considered a viable treatment option for thoracic chordomas.

  • Open Access

    Patient-Derived Training Simulator for Image-Guided Adaptive Brachytherapy of Locally Advanced Cervical Cancers: Development and Initial Use

    by Kento Tomizawa, Takahiro Oike, Ken Ando, Daisuke Irie, Makoto Sakai, Hirofumi Shimada, Tatsuya Ohno

    Image-guided adaptive brachytherapy (IGABT) using intracavitary and interstitial (IC/IS) techniques plays a pivotal role in definitive radiotherapy for locally advanced cervical cancers. However, the training opportunities for interstitial needle application are limited, preventing this technique from becoming widespread. This study aimed to develop a training simulator for IC/IS brachytherapy. The simulator consists of a soft silicone tumor phantom and acrylic tube mimicking the vagina; it has high visibility because of translucent materials and is compatible with computed tomography (CT) and magnetic resonance imaging (MRI). A patient harboring a typical bulky and irregular-shaped cervical tumor was selected from 495 in-house IGABT-treated candidates, and a tumor phantom (68 × 49 × 45 mm) modeled on this patient was produced from three-dimensional real-scale measurements of the MRI-based high-risk clinical target volume at first brachytherapy. In trial use by two physicians with different levels of IGABT skills, a Fletcher-Suit Asian Pacific applicator, and a Venezia applicator with interstitial needles were nicely applied to the simulator, facilitating successful creation of CT-based treatment plans consistent with clinical practice. Thus, the training simulator can be useful for the training of IC/IS brachytherapy, and warrants further research employing a greater number of phantoms and practitioners to verify its educational value.


  • Open Access

    Locally Advanced Breast Cancer Involving the Skin Surface Treated With Radiation Therapy Using a Hydrogen Peroxide Solution–Soaked Gauze Bolus: A Case Report

    by Shintaro Shiba, Tetsuya Watanabe, Takuya Kaminuma, Etsuko Miyamoto, Motohiro Kawashima, Daisuke Irie, Ken Ando, Tatsuya Ohno


  • Open Access

    Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix

    by Noriyuki Okonogi, Ken Ando, Kazutoshi Murata, Masaru Wakatsuki, Shin-Ei Noda, Daisuke Irie, Hiroshi Tsuji, Makio Shozu, Tatsuya Ohno

    The clinical significance of carbon-ion radiotherapy (CIRT) for adenocarcinoma (AC) of the uterine cervix has been assessed in several single-institutional studies. To validate the significance, we conducted a multi-institutional survey of CIRT for locally advanced AC (LAAC) of the uterine cervix. We retrospectively analyzed the clinical outcomes of patients with stage IIB–IVA LAAC of the uterine cervix who underwent chemo-CIRT or CIRT alone between April 2010 and April 2016. Patients received 74.4 Gy (relative biological effectiveness [RBE]) in 20 fractions of CIRT or 55.2 Gy (RBE) in 16 fractions of CIRT plus three sessions of brachytherapy. Patients aged ≤ 70 years with adequate bone marrow and organ function were administered cisplatin weekly (40 mg/m2 per week for up to 5 weeks). Fifty-five patients were enrolled in this study. The median follow-up period was 67.5 months. The 5-year overall survival (OS) and local control (LC) rates were 68.6% and 65.2%, respectively. Multivariate analysis showed that the initial tumor response within 6 months was significantly associated with LC and OS. The present study represents promising outcomes of CIRT or chemo-CIRT for LAAC of the uterine cervix, especially in the cases showing initial rapid regression of the tumor.


  • Open Access

    Induction of Micronuclei in Cervical Cancer Treated with Radiotherapy

    by Daijiro Kobayashi, Takahiro Oike, Kazutoshi Murata, Daisuke Irie, Yuka Hirota, Hiro Sato, Atsushi Shibata, Tatsuya Ohno

    Micronuclei (MN) trigger antitumor immune responses via the cyclic GMP-AMP synthase-signaling effector stimulator of interferon genes (cGAS-STING) pathway. Radiotherapy induces MN in peripheral blood lymphocytes. However, data for solid tumors are lacking. Here, we analyzed MN post-radiotherapy in solid tumor samples. Tumor biopsy specimens were obtained from seven prospectively recruited patients with cervical cancer, before treatment and after receiving radiotherapy at a dose of 10 Gy (in five fractions). The samples were stained with 4′,6-diamidino-2-phenylindole dihydrochloride, and 200 nuclei per sample were randomly identified and assessed for the presence of MN or apoptosis, based on nuclear morphology. The median number of MN-harboring nuclei was significantly greater in samples from patients treated with radiotherapy than in pre-treatment samples (151 (range, 16–327) versus 28 (range, 0–61); p = 0.015). No significant differences in the number of apoptotic nuclei were observed between pre-treatment and 10 Gy samples (5 (range, 0–30) versus 12 (range, 2–30); p = 0.30). This is the first report to demonstrate MN induction by radiotherapy in solid tumors. The results provide clinical evidence of the activation of antitumor immune responses by radiotherapy.


  • Open Access

    FIGO 2018 Staging for Cervical Cancer: Influence on Stage Distribution and Outcomes in the 3D-Image-Guided Brachytherapy Era

    by Kento Tomizawa, Takuya Kaminuma, Kazutoshi Murata, Shin-Ei Noda, Daisuke Irie, Takuya Kumazawa, Takahiro Oike, Tatsuya Ohno

    Recent widespread use of three-dimensional image-guided brachytherapy (3D-IGBT) has improved radiotherapy outcomes of cervical cancer dramatically. In 2018, the International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer was revised. However, the influence of the revisions on the stage distribution and outcomes of cervical cancers treated with 3D-IGBT remains unclear. Here, we retrospectively analyzed 221 patients with cervical squamous cell carcinoma treated with definitive radiotherapy using 3D-IGBT (median follow-up, 60 months). The stage distribution and outcomes were compared between the 2009 and 2018 schemas. Stage migration occurred in 52.9% of the patients. Patients classified with the 2018 criteria as stage IIICr had the highest proportion (43.8%) of migration, and were mainly from the 2009 stages IIB and IIIB. The 2009 and 2018 schemas showed comparable performance at stratifying 5-year overall survival (OS) and 5-year progression-free survival (PFS) for patients in stages IB–IVA. The 2018 criteria effectively stratified 5-year OS and PFS in the stage III substages. The 5-year OS and PFS for stage IIIC1r patients varied according to tumor T stage. These data provide evidence for the utility of the revised 2018 FIGO staging system in the clinical management of cervical cancers in the 3D-IGBT era.


  • Open Access

    Oral Gastrografin Facilitates Delineation of Intestinal Tracts in CT-Based Brachytherapy for Uterine Cervical Cancer

    by Daisuke Irie, Kazutoshi Murata, Takuya Kaminuma, Takahiro Oike, Tatsuya Ohno

    Three-dimensional image-guided brachytherapy (3D-IGBT) using computed tomography (CT) is an essential component of definitive radiation therapy for uterine cervical cancer (UCC). Treatment planning for CT-based 3D-IGBT requires delineating the high-risk clinical target volume (CTVHR) and the organs at risk (OARs), which is difficult when the small intestine is adjacent to those delineation targets. Uncertainty in target delineation threatens the validity of 3D-IGBT treatment plans. To address this issue, we introduce the use of diatrizoate meglumine and diatrizoate sodium (gastrografin), an orally administrable iodine-based radiopaque contrast agent. We present two cases of UCC treated with CT-based 3D-IGBT and describe how intraluminal enhancement of the small intestine by oral gastrografin pretreatment facilitated discrimination between the small intestine and the adjacent CTVHR (case no.1) or the rectosigmoid colon (case no. 2). Oral gastrografin pretreatment is a simple and cost-effective method that allows distinguishing the small intestine from the adjacent delineation target (i.e., CTVHR and the OARs) in CT-based 3D-IGBT for UCC.